Clinicopathological and functional analysis of carbohydrate antigen expression : Focusing on DU-PAN-2 (precursor of CA19-9)

对子宫内膜腺癌(EAC)患者血清糖类抗原DU-PAN-2和CA19-9的升高进行了研究，尤其是对DU-PAN-2的表达谱进行了研究。手术切除子宫内膜样型子宫内膜样癌64例。检测各标志物的术前血清值，并对其与组织学分级和临床病理分期的关系进行对比分析。DU-PAN-2和CA19-9的总阳性率分别为26.2%和25.0%。DU-PAN-2随分级升高而降低，而CA19-9则相反。从I+II期到III+IV期，阳性率依次为：DU-PAN-2，18.4%~53.3%，CA19-9，20.4%~40.0%。提示DU-PAN-2倾向于在EACS的高分化成分中比在低分化成分中产生更多。由于在III+IV期，大约一半的袋子病例的血清DU-PAN-2呈阳性，因此该标志物被认为在监测宫外病例方面有很大的用处。

Serum elevations of carbohydrate antigens ; DU-PAN-2 and CA19-9 in endometrial adenocarcinomas (EACs) were characterized, particularly focusing on clarification of DU-PAN-2 expression profiles. Sixty-four resected EACs of endometrioid type were used. The preoperative serum values of the markers were measured and comparatively analyzed regarding the relationship between histological grade and clinicopathological stage. The overall ratios of positive cases were 26.2% for DU-PAN-2 and 25.0% for CA19-9. DU-PAN-2 decreased as the grading went up, however the reverse was true with CA19-9. During staging-up from I+II to III+IV, the positive ratios inclined as follows : DU-PAN-2, 18.4% to 53.3% ; CA19-9, 20.4% to 40.0%. It is suggested that DU-PAN-2 tends to be produced more in well-differentiated components of EACs than in poorly-differentiated ones. Since approximately half the cases with BAGs were serologically positive for DU-PAN-2 in stage III+IV, the marker is believed to be one of much use for monitoring the cases with an extrauterine extent.